Lenalidomide Orion (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s target profile, leading to degradation of transcription factors Ikaros and Aiolos, which in turn produces anti‑angiogenic, immunomodulatory, and anti‑proliferative effects on malignant cells.

The specific dose and schedule of Lenalidomide Orion are determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Only a qualified health‑care professional should set the dosage.

Lenalidomide Orion is classified as pregnancy category X because it can cause severe fetal harm. It is contraindicated in pregnant women and should not be used by women who are breastfeeding. Effective contraception is required for both men and women of reproductive potential during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, which can be more convenient, and is often combined with dexamethasone or other agents to enhance efficacy, especially in relapsed or refractory disease.

Lenalidomide Orion should be stored at temperatures below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Lenalidomide Orion is taken orally, usually once daily, with or without food, as directed by the treating physician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include severe neutropenia or thrombocytopenia, which can lead to infections or bleeding, and venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Additionally, the drug is teratogenic and can cause fetal harm if exposure occurs during pregnancy.

Lenalidomide Orion should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled infections or severe renal impairment without appropriate dose adjustment. Clinicians must evaluate each patient’s medical history before prescribing.